Phone
+39 010 2896 983
Address
Via Morego, 30 16163 Genova
Research center
CCT@Morego
All Publications
2025
Rinaldi F., Balboni B., Varignani G., Milordini G., Marotta R., Girotto S., Cavalli A.
An integrative structural study of RAD52, an emerging target in anticancer drug discovery
XXIX National Meeting on Medicinal Chemistry of the Italian Chemistry Society
Poster
Conference
2025
Rinaldi F., Balboni B., Girotto S., Cavalli A.
An integrative structural study of RAD52, an emerging target in anticancer drug discovery
XXIX National Meeting on Medicinal Chemistry of the Italian Chemistry Society
Poster
Conference
2025
Rinaldi F., Franco P., Veronesi M., Romeo E., Bresciani V., Varignani G., Catalano F., Bernetti M., Masetti M., Langer J. D., Girotto S., Cavalli A.
Breaking new ground into RAD51–BRC repeats interplay in Homologous Recombination
Research Square
Article
E-print Archive
2025
Cianci F., Verduci I., Cazzoli R., Cannavale G., Rey G., Veronesi M., Balboni B., Ranucci M., Palloni L.M.G., Ballabio F., Barsotti N., Ailuno G., Balboni A., Baldassari S., Caviglioli G., Tacconi C., Camilloni C., Girotto S., Barbieri F., Fantin A., Cavalli A., Pasqualetti M., Florio T., Minucci S., Mazzanti M.
Chronic administration of metformin exerts cytostatic and cytotoxic effects via the PP2A-GSK3β-MCL-1 pathway by inhibiting the tmCLIC1 membrane protein in glioblastoma-initiating cells
Journal of Experimental and Clinical Cancer Research, vol. 44, (no. 1)
Article
Journal
2025
Milordini G., Zacco E., Armaos A., Di Palma F., Masi M., Gilodi M., Rupert J., Broglia L., Varignani G., Oneto M., Scotto M., Marotta R., Girotto S., Cavalli A., Tartaglia G.G.
Computationally-designed aptamers targeting RAD51-BRCA2 interaction inhibit RAD51 nuclear recruitment
bioRxiv
Article
E-print Archive